Print this page    •   Back to Web version of article

Information
An Overview of Viramune (Nevirapine)

May 6, 2015

Nevirapine Nevirapine Oralviramune XR 400mgviramune XR 100mg

Brand Name: Viramune XR, Viramune
Other Name(s): extended-release nevirapine, NVP
Drug Class: Non-nucleoside Reverse Transcriptase Inhibitors
Approved Use: Treatment of HIV Infection


Chemical Image

nevirapine chemical image

nevirapine
Molecular Weight: 266.303


WARNING:

Nevirapine can cause serious, life-threatening side effects. These include severe liver problems, skin rash, and skin reactions. The liver and skin problems can happen at any time during treatment, but the time of greatest risk is during the first 18 weeks of treatment.

Stop taking nevirapine and contact your health care provider right away if you have any of the following symptoms that could be signs of liver problems:

Stop taking nevirapine and contact your health care provider right away if you have a skin rash with any of the following symptoms:

If your health care provider tells you to stop treatment with nevirapine because of serious liver or skin problems, you should never take nevirapine again.

While taking nevirapine, it is important to keep all of your appointments with your health care provider.


What Is Nevirapine?

Nevirapine is a prescription medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of HIV infection. Nevirapine comes in three different forms: immediate-release tablets, extended-release tablets, and a liquid (oral suspension). The immediate-release tablet and liquid forms of nevirapine are approved for use in adults and children 15 days and older. The extended-release tablets are approved for use only in those 6 years and older. Nevirapine is always used in combination with other HIV medicines.

Nevirapine belongs to a class (group) of HIV drugs called non-nucleoside reverse transcriptase inhibitors (NNRTIs). NNRTIs attach to and block an HIV enzyme called reverse transcriptase. (An enzyme is a protein that starts or increases the speed of a chemical reaction.) By blocking reverse transcriptase, NNRTIs prevent HIV from multiplying and can reduce the amount of HIV in the body.

HIV medicines can't cure HIV/AIDS, but taking a combination of HIV medicines (called an HIV treatment regimen) every day helps people with HIV live longer, healthier lives. HIV medicines also reduce the risk of HIV transmission.


What Should I Tell My Health Care Provider Before Taking Nevirapine?

Before taking nevirapine, tell your health care provider:


How Should I Take Nevirapine?

Nevirapine comes in the following forms and strengths:

Take nevirapine according to your health care provider's instructions.

To reduce the risk of skin rash, a low dose of nevirapine is given for the first 14 days of treatment. If you get a skin rash during the first 14 days of nevirapine treatment, call your health care provider right away. Do not increase your nevirapine dose to 2 times a day if you have a rash.

Take nevirapine with or without food. Never take more than one form of nevirapine at the same time.

Nevirapine extended-release tablets are not for use in children less than 6 years of age. The extended-release tablets should be swallowed whole and should not be chewed, crushed, or divided. Do not start taking nevirapine extended-release tablets if you have a rash.

Nevirapine oral suspension is a liquid. Shake it gently before each use, and use an oral dosing syringe or dosing cup to measure the right dose. If the dose is less than 1 teaspoon (5 mL), use a syringe to measure the dose. (Ask your pharmacist for a syringe or dosing cup if you do not have one.) After drinking the medicine, fill the dosing cup with water and drink it to make sure you get all the medicine.

Always take nevirapine in combination with other HIV medicines.

If you take too much nevirapine, contact your health care provider or local poison control center (1-800-222-1222) right away, or go to the nearest hospital emergency room.

For more information on how to take nevirapine, see the FDA drug labels for nevirapine immediate-release tablets (brand name: Viramune), nevirapine extended-release tablets (brand name: Viramune XR), and nevirapine oral suspension (brand name: Viramune), from DailyMed. (DailyMed is a federal website that includes the most recent drug labels submitted to FDA.)


What Should I Do if I Forget a Dose?

If you miss a dose of nevirapine, take the missed dose as soon as you remember it. But if it is almost time for your next dose, skip the missed dose and just take your next dose at the regular time. Do not take two doses at the same time to make up for a missed dose. If you stop taking nevirapine for more than 7 days, ask your health care provider how much to take before you start taking it again.


What Side Effects Can Nevirapine Cause?

Nevirapine can cause serious, life-threatening side effects. These include severe liver problems, skin rash, and skin reactions. The liver and skin problems can happen at any time during treatment, but the time of greatest risk is during the first 18 weeks of treatment. (See the WARNING above.)

Other possible side effects of nevirapine include:

Tell your health care provider if you have any side effect that bothers you or that does not go away.

These are not all the possible side effects of nevirapine. To learn more about possible side effects of nevirapine, read the drug label or package insert or talk to your health care provider or pharmacist.

The AIDSinfo fact sheet on HIV Medicines and Side Effects also includes information that may apply to nevirapine.

You can also report side effects to FDA at 1-800-FDA-1088 (1-800-332-1088) or online at www.accessdata.fda.gov/scripts/medwatch/.


How Should Nevirapine Be Stored?


Where Can I Find More Information About Nevirapine?

More information about nevirapine is available:


Manufacturer Information

Boehringer Ingelheim
800-243-0127

The above Patient Version drug summary is based on the following FDA label(s): Suspension, tablet; Tablet (extended release).




This article was provided by AIDSinfo. You can find this article online by typing this address into your Web browser:
http://www.thebody.com/content/art4300.html

General Disclaimer: TheBody.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBody.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.